Diakom s.r.o.
- Address
- Husova 760, 33401 Prestice, Czechia
Diakom s.r.o. - Obesity and Metabolic Health Research
Diakom s.r.o. is a clinical research center dedicated to advancing therapeutic interventions for metabolic disorders and their associated complications. The center specializes in investigating novel pharmacological approaches to address obesity and its serious cardiovascular and renal consequences, contributing to the development of comprehensive treatment strategies for patients living with metabolic syndrome.
- Cardiovascular outcomes research in obesity management
- Kidney function preservation and renal outcomes studies
- Novel therapeutic agents for weight management and metabolic disease
The center's research portfolio emphasizes the critical intersection of obesity, cardiovascular health, and kidney function, recognizing that effective obesity treatment must address not only weight reduction but also the prevention of serious organ-related complications. Through participation in large-scale outcomes trials, Diakom s.r.o. contributes valuable clinical data that shapes evidence-based approaches to managing patients with overweight and obesity-related comorbidities.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diakom s.r.o.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of MF59-Adjuvanted Influenza Vaccine Versus Non-Adjuvanted Vaccine in Adults Aged 65 and Older | Seqirus UK Limited | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227) | 1 | Unknown | 2023-10-20 | 2023-10-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.